Sanofi scraps a PhII IL4/IL13 development program for lung scarring disease
Sanofi and Regeneron have scored big with the IL4/IL13 pathway, which has proved to be a blockbuster approach for their drug Dupixent (dupilumab). But Sanofi …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
